http://www.jvir.org/article/S1051-0443(16)30181-6/abstract...

http://www.jvir.org/article/S1051-0443(16)30181-6/abstract

Results

Toxicities included 1 cholecystitis (grade 2) and 1 duodenal ulceration (grade 3); no grade ≥ 4 clinical toxicities were noted. Objective response rate (complete + partial response) was 28.9% (11/38); disease control rate (response + stable disease) was 71.1% (27/38). Median time to progression of treated liver lobe was 101 days (range, 30–2,037 d). During follow-up, 34/42 patients died (median OS after first TARE: 184 d [range 29–2,331 d]). On multivariate analysis, baseline Eastern Cooperative Oncology Group (ECOG) status of 0 (P < .0001, hazard ratio [HR] = 0.146) and low baseline γ-glutamyltransferase (GGT) levels (P = .0146, HR = 0.999) were predictors of longer OS.
Conclusions

TARE can successfully delay progression of therapy-refractory LdBM with low complication rate. Nonelevated baseline ECOG status and low GGT levels were identified as prognostic factors.

---------------------------------
Would be interested to see the full text ??

Of note - Median to progression was 101 days, and median OS was 184 days. Anyone have data to hand for folks not having TARE?